HYDROMORPHONE HYDROCHLORIDE INJECTION, USP SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Купи го сега

Активна съставка:

HYDROMORPHONE HYDROCHLORIDE

Предлага се от:

FRESENIUS KABI CANADA LTD

АТС код:

N02AA03

INN (Международно Name):

HYDROMORPHONE

дозиране:

10MG

Лекарствена форма:

SOLUTION

Композиция:

HYDROMORPHONE HYDROCHLORIDE 10MG

Начин на приложение:

INTRAMUSCULAR

Броя в опаковка:

15G/50G

Вид предписание :

Narcotic (CDSA I)

Терапевтична област:

OPIATE AGONISTS

Каталог на резюме:

Active ingredient group (AIG) number: 0108698001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2019-08-21

Данни за продукта

                                HYDROmorphone Hydrochloride Injection, USP - 2 mg/mL
Page 1 of 34
PRESCRIBING INFORMATION
INCLUDING PATIENT MEDICATION INFORMATION
N
HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
(Hydromorphone Hydrochloride Injection, USP)
2 mg/mL Sterile Solution for Injection
Intramuscular, Intravenous, Subcutaneous
Opioid Analgesic
NOT A PRODUCT MONOGRAPH
Fresenius Kabi Canada Ltd.
Date of revision:
165 Galaxy Blvd. Suite 100
August 20, 2019
Toronto, Ontario
M9W 0C8
Submission Control No.: 212894
HYDROmorphone Hydrochloride Injection, USP - 2 mg/mL
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 3
SUMMARY PRODUCT INFORMATION
........................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................................
3
CONTRAINDICATIONS
...................................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................................
4
ADVERSE REACTIONS
.................................................................................................................
12
DRUG INTERACTIONS
..................................................................................................................
15
DOSAGE AND ADMINISTRATION
..............................................................................................
16
OVERDOSAGE
................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
............................................................................
20
STORAGE AND STABILITY
.........................................................................................................
22
SPECIAL HANDLING INSTRUCTIONS
.....................................................
                                
                                Прочетете целия документ
                                
                            

Документи на други езици

Данни за продукта Данни за продукта френски 20-08-2019

Сигнали за търсене, свързани с този продукт

Преглед на историята на документите